The brain metastasis therapeutics market is expected to advance at a CAGR of 7.8% during the forecast period. The valuation of the market as of 2023 is US$ 3,269.8 million. The market is expected to be valued at US$ 6,915.2 million by 2033.
An increase in cancer cases, especially cerebrum malignancy, improving medical infrastructure, and many other activities are expected to increase the demand for brain metastasis therapeutics during the forecast period.
| Report Attribute | Details |
|---|---|
| Brain Metastasis Therapeutics Market Valuation in 2023 | US$ 3,269.8 million |
| Brain Metastasis Therapeutics Market Anticipated Value (2033) | US$ 6,915.2 million |
| Brain Metastasis Therapeutics Market Projected Growth Rate (2023 to 2033) | 7.8% |
Brain metastasis is typically cancer due to the spread of cancerous cells to the brain. Brain metastasis is more common as compared to primary brain cancer. Some known brain metastasis causes include a rapid spread in the cancer cells due to breast cancer, lung cancer, melanoma, renal cell carcinoma, and colon cancer.
The brain metastasis diagnosis is usually made using CAT/CT scan or MRI. Thanks to the increased penetration of these services, the diagnosis can be made in no time, and the patient can undergo the necessary treatment.
The diagnosis and rapid technological advancements have allowed the patient to undergo treatment within a few weeks, helping him lead an everyday life. This is anticipated to increase the demand for brain metastasis therapeutics during the forecast period.
Even the stats indicate that there might be an increase in the application of brain metastasis therapeutics in the coming times. The historical CAGR for the market was 5.1%, and the anticipated CAGR for the forecast period is 7.8%. The increase in forecast CAGR compared to the historical CAGR is undoubtedly projected to be instrumental in transforming lives for good.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Increase in Cancer Cases:
A survey conducted by WHO found that cancer was the leading cause of death worldwide in 2020, and around 10 million people died of cancer. The most common types of cancer recorded were breast cancer (2.26 million cases) and lung cancer (2.21 million cases).
When cancer develops in some body parts, it gradually spreads to other parts of the body, reaching the brain and causing brain metastasis. Because of this, the demand for brain metastasis therapeutics is expected to increase.
Efficient Medical Infrastructure:
There has been a tremendous improvement in the medical infrastructure. This is mainly because of the evolving technology. This evolution has allowed doctors and physicians to work synchronously and carry out medical operations effectively. Moreover, the evolution of 3D printing has made it easier to locate the affected area in the brain with higher precision and clarity.
Apart from all this, the biggest boon is the reduced risk and recovery time. Because of technological innovations, treatments like laser surgery and other medical procedures are now less invasive. This is anticipated to increase the brain metastasis therapeutics market share.
High cost of treatment: The brain metastasis therapeutics treatment is quite costly, and despite wanting to avail of the service, many people are not able to take up the treatment, as a result of which their condition worsens.
Side effects: The biggest restraint that is plaguing the brain metastasis therapeutics market is the side effects that the patient has to face during and after the treatment. Some of the side effects include vomiting, weakness, seizures, etc.
Principal Consultant
Of late, there has been an increasing adoption of Ayurveda and Yoga. These are believed to be highly harmless methods for resolving health issues. The time taken to show visible effects might be high, but experts are of the opinion that the effects are long-lasting.
If we talk about Yoga, there is no side effect involved, as it involves experimenting entirely with the body and focusing on the breathing pattern. Many scientists believe that cancer results from inadequate oxygen flow to certain parts of the body, and Yoga helps resolve that.
However, Ayurveda, on the other is more about treating health issues using ancient Indian techniques, which mainly involves the usage of herbs and certain kinds of spices. In many cases, Ayurveda has successfully delivered the required results for almost any kind of patient. Thus, the increased adoption of Ayurveda and Yoga might negatively impact the brain metastasis therapeutics industry outlook.
| Region | North America |
|---|---|
| Market Share % (2022) | 35% |
The North American brain metastasis therapeutics industry, which currently has a market share of around 35%, is expected to be one of the largest markets during the forecast period.
A study conducted in 2018 by ‘The Cancer Atlas’ found that there were nearly 1.9 million new cancer cases in 2018, apart from the existing ones. Moreover, North America is also meant for people who suffer from lifestyle diseases, and cancer is also believed to be caused by lifestyle diseases in many cases. With so many health-related issues affecting the region, it is anticipated that brain metastasis therapeutics adoption trends is expected to positively influence the region.
| Region | Europe |
|---|---|
| Market Share % (2022) | 24.5% |
The European brain metastasis therapeutics industry, which has a share of 24.5%, is expected to be one of the most significant regions during the forecast period.
The region is meant for people to take proactive steps if they get a hint regarding any health-related issues. Moreover, people in this region can afford various health services because of the active involvement of the government in such activities. Moreover, the region has witnessed higher technological innovations, which have made brain metastasis therapeutics treatment much more efficient in the region.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
There is not much happening in the start-up ecosystem of the brain metastasis therapeutics industry, and the market is dominated only by the players who have been serving this niche for a long time.
But, with so many angel investors looking for entrepreneurs willing to start a business in this niche, this niche represents many opportunities. Moreover, with rapid technological advancements in the medical sector, start-ups can make the best use of this situation and can come up with innovative ways to cure such health issues.
The key players in the brain metastasis therapeutics market are looking for ways to further diversify their portfolios. They are doing this through mergers, acquisitions, or opening new centers. Additionally, these players have also been involved in demergers to stop operating in markets that are of no use.
Some of the key players are Bayer AG, Pfizer Inc., Sanofi, F. Hoffmann-La Roche Ltd., Eli Lilly & Company, Novartis AG, GlaxoSmithKline, Merck & Co., Inc., AstraZeneca, and AngioChem Inc.
Some of the recent developments are:
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 7.8% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US$ million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
The brain metastasis therapeutics market is set to reach US$ 3,269.8 million in 2023, with sales potentially surging to US$ 6,915.2 million by 2033, exhibiting a 7.8% CAGR.
The global brain metastasis therapeutics market registered a CAGR of 5.1% between 2018 and 2022.
Advancements in targeted therapies, precision medicine, and neuroimaging techniques significantly impact brain metastasis therapeutics market growth.
North America stands as a prominent player in the brain metastasis therapeutics landscape, owing to its strong clinical trial infrastructure.
Radiation therapy prevails in brain metastasis therapeutics, excelling in targeted treatment for metastatic brain tumors.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Treatment Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment Type, 2023 to 2033
5.3.1. Radiation Therapy
5.3.2. Chemotherapy
5.3.3. Targeted Therapy
5.3.4. Anticonvulsants
5.3.5. Corticosteroids
5.4. Y-o-Y Growth Trend Analysis By Treatment Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Treatment Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End Use
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By End Use, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End Use, 2023 to 2033
6.3.1. Cancer Hospitals
6.3.2. Clinics
6.3.3. Cancer Research Centers
6.4. Y-o-Y Growth Trend Analysis By End Use, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By End Use, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Western Europe
7.3.4. Eastern Europe
7.3.5. South Asia and Pacific
7.3.6. East Asia
7.3.7. Middle East and Africa
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. USA
8.2.1.2. Canada
8.2.2. By Treatment Type
8.2.3. By End Use
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Treatment Type
8.3.3. By End Use
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Treatment Type
9.2.3. By End Use
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Treatment Type
9.3.3. By End Use
9.4. Key Takeaways
10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. UK
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Western Europe
10.2.2. By Treatment Type
10.2.3. By End Use
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Treatment Type
10.3.3. By End Use
10.4. Key Takeaways
11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Poland
11.2.1.2. Russia
11.2.1.3. Czech Republic
11.2.1.4. Romania
11.2.1.5. Rest of Eastern Europe
11.2.2. By Treatment Type
11.2.3. By End Use
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Treatment Type
11.3.3. By End Use
11.4. Key Takeaways
12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Bangladesh
12.2.1.3. Australia
12.2.1.4. New Zealand
12.2.1.5. Rest of South Asia and Pacific
12.2.2. By Treatment Type
12.2.3. By End Use
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Treatment Type
12.3.3. By End Use
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Treatment Type
13.2.3. By End Use
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Treatment Type
13.3.3. By End Use
13.4. Key Takeaways
14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of MEA
14.2.2. By Treatment Type
14.2.3. By End Use
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Treatment Type
14.3.3. By End Use
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. USA
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2022
15.1.2.1. By Treatment Type
15.1.2.2. By End Use
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2022
15.2.2.1. By Treatment Type
15.2.2.2. By End Use
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2022
15.3.2.1. By Treatment Type
15.3.2.2. By End Use
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2022
15.4.2.1. By Treatment Type
15.4.2.2. By End Use
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2022
15.5.2.1. By Treatment Type
15.5.2.2. By End Use
15.6. UK
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2022
15.6.2.1. By Treatment Type
15.6.2.2. By End Use
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2022
15.7.2.1. By Treatment Type
15.7.2.2. By End Use
15.8. Spain
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2022
15.8.2.1. By Treatment Type
15.8.2.2. By End Use
15.9. Italy
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2022
15.9.2.1. By Treatment Type
15.9.2.2. By End Use
15.10. Poland
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2022
15.10.2.1. By Treatment Type
15.10.2.2. By End Use
15.11. Russia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2022
15.11.2.1. By Treatment Type
15.11.2.2. By End Use
15.12. Czech Republic
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2022
15.12.2.1. By Treatment Type
15.12.2.2. By End Use
15.13. Romania
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2022
15.13.2.1. By Treatment Type
15.13.2.2. By End Use
15.14. India
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2022
15.14.2.1. By Treatment Type
15.14.2.2. By End Use
15.15. Bangladesh
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2022
15.15.2.1. By Treatment Type
15.15.2.2. By End Use
15.16. Australia
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2022
15.16.2.1. By Treatment Type
15.16.2.2. By End Use
15.17. New Zealand
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2022
15.17.2.1. By Treatment Type
15.17.2.2. By End Use
15.18. China
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2022
15.18.2.1. By Treatment Type
15.18.2.2. By End Use
15.19. Japan
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2022
15.19.2.1. By Treatment Type
15.19.2.2. By End Use
15.20. South Korea
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2022
15.20.2.1. By Treatment Type
15.20.2.2. By End Use
15.21. GCC Countries
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2022
15.21.2.1. By Treatment Type
15.21.2.2. By End Use
15.22. South Africa
15.22.1. Pricing Analysis
15.22.2. Market Share Analysis, 2022
15.22.2.1. By Treatment Type
15.22.2.2. By End Use
15.23. Israel
15.23.1. Pricing Analysis
15.23.2. Market Share Analysis, 2022
15.23.2.1. By Treatment Type
15.23.2.2. By End Use
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Treatment Type
16.3.3. By End Use
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Bayer AG
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. Pfizer Inc.
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. Sanofi
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. F. Hoffmann-La Roche Ltd.
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. Eli Lilly & Company
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. Novartis AG
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. GlaxoSmithKline
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. Merck & Co. Inc.
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. AstraZeneca
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. AngioChem Inc.
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Explore Healthcare Insights
View Reports
Brain Metastasis Therapeutics Market
